Oncoinvent (ONCIN) Investor update summary

Executive summary

• RadspherinⓇ, a receptor-independent alpha radiopharmaceutical, is in clinical development for ovarian and colorectal cancers and targets cancer cells in the abdominal cavity.

• Key milestones included positive Phase 1 ovarian cancer data, ongoing Phase 2 recruitment, a new Chinese patent and the appointment of CFO Dr. Ramzi Amri.

Financial highlights

• Cash and cash equivalents totaled NOK 130 million at March 31, 2026.

• Current cash reserves are expected to fund operations into 2027.

Outlook and guidance

• Clinical R&D expenses are expected to scale with recruitment; no material change to near-term operating cash burn is anticipated, and spending remains aligned with recruitment and milestones.

• Exploring strategic partnerships, business development and financing options to extend runway and support pivotal studies and potential market entry.

• Plans include adding trial hospitals and using protocol adjustments and digital tools to optimize enrollment.